Official journal of the Slovak Society of Cardiology,
Slovak Society of Hypertension and Slovak Association for Cardiac Arrhythmias

Cardiology Letters 2018, 27(2):94-98

Ischaemic heart disease - which way can treatment of hypertension help us here?

Murín J
I. interná klinika LFUK a UNB, nemocnica Staré Mesto, Mickiewiczova 3, 813 69 Bratislava, Slovenská republika

Ischaemic heart disease (IHD) is the most common disease in clinical practice with the highest morbidity and mortality. Arterial hypertension is one of most frequent risk factors for IHD together with dyslipidemia. Prevention of development/progression of IHD with good treatment of cardiovascular risk factors, mostly hypertension, is a good step in improving the cardiovascular prognosis of these patients. This article discusses pathways of IHD development through hypertension, and the pathways of development in ischaemic events. It tries to show us also the best treatment possibilities in patients with hypertension and ischaemic heart disease together. The author stresses the use of betablocker and of ACE inhibitor in the treatment of these patients, and stresses the importance of adherence to the treatment, and focusses the treatment on the fixed combination in one tablet of bisoprolol-perindopril.

Keywords: ischaemic heart disease; hypertension; treatment of a patient with hypertension and ischaemic heart disease; fixed combination of bisoprolol-perindopril

Published: February 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Murín J. Ischaemic heart disease - which way can treatment of hypertension help us here? Cardiology Letters. 2018;27(2):94-98.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Murray ChJL, Lopez AD. Measuring the global burden of disease. N Engl J Med 2013;369:448-457. Go to original source...
    2. Murín J, Kamenský G. Register CLARIFY - pohľad na Slovenské údaje po piatich rokoch. Cardiology Lett 2017;26:236-246.
    3. Svihrova V, Barakova A, Szaboova M, et al. Trends in standardized mortality rates for select groups of cardiovascular diseases in Slovakia between 1980 and 2010. Public health 130 (2016) 43-50 (http://dx.doi.org/10.1016Pj.puhe.2015.09.006) Go to original source...
    4. Kamenský G, Murín J a kolektív. Kardiovaskulárne ochorenia - najväčšia hrozba. Biela kniha. Bratislava: AEPress s.r.o.; 2009:221. (ISBN 978-80-88880-86-8)
    5. Fihn SD, Gardin J, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/ PCNA/ACAI/STS Guideline on the diagnosis and management of patients with stable ischemic heart disease: a report of many societies. Circulation 2012;126:e354-e471.
    6. Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force of the ESC. Eur Heart J 2013;34:2949-3003. Go to original source...
    7. Canty JM jr. Coronary pressure- function and steady-state pressureflow relations during autoregulation in the unanesthetized dog. Circ Res 1988;63:821-836. Go to original source...
    8. Rouleau J, Simard D, Blouin A, Kingma JG Jr. Angiotensin Inhibition and Coronary Autoregulation in a Canine Model of LV Hypertrophy. Basic Research in Cardiology 2002;97:384-391. Go to original source...
    9. Ghanem WMA, Murín J, Bulas J. Hypertrofia ľavej komory etiopatogenéza, klinické dôsledky a prognóza. Vnitr Lek 1999;45:421-428.
    10. Lewington S, Clarke R, Qizilbash N, et al. (prospective studies collaboration). Age-specific relevance of usual blood pressure to vascular mortality:a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903/1913. Go to original source...
    11. Steg PG. Heart rate management in coronary artery disease: the CLARIFY registry. Eur Heart J Suppl. 2009;11(Suppl. D):D13D18. Go to original source...
    12. Steg PG, Greenlaw N, Tardif JC, et al. Women and men with stable coronary artery disease have similar clinical outcomes: insights from international prospective CLARIFY registry. Eur Heart J 2012;33:2831-2840. Go to original source...
    13. SPRINT Research Group. A randomized trial of intensive versus standard blood/pressure control. N Engl J Med 2015;373:21032016. Go to original source...
    14. Steg PG, Ferrari R, Ford I, et al. Heart rate and use of beta-blockers in stable outpatients with coronary artery disease. PloS One 2012;7:e 36 284 Go to original source...
    15. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013 Jul;31(7):1281-357. Go to original source...
    16. Pepine CJ, Handberg EM, Cooper/DeHoff RM, et al for the INVEST Investigators A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International VerapamilTrandolapril Study (INVEST): a randomized controlled trial. JAMA 2003;290:2805-2816. Go to original source...
    17. Leizorovicz A, Lechat P, Cucherat M, Bugnard F. Bisoprolol for the treatment of chronic heart failure: a meta-analysis on individual data of two placebo-controlled studies - CIBIS and CIBIS II. Cardiac Insufficiency Bisoprolol Study. Am Heart J 2002;143(2):301-307. Go to original source...
    18. Krum H, van Veldhuisen D, Funck-Brentano Ch, et al. Effect on mode of death of heart failure treatment started with bisoprolol folowed by enalapril, compared to the opposite order: results of the randomized CIBIS III Trial. Cardiovascular Therapeutics. 2011(29):89-98. Go to original source...
    19. Patel, A and ADVANCE Collaborative Group. Effect of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829-840. Go to original source...
    20. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033-1041. Go to original source...
    21. Bertrand ME, Ferrari R, Remme WJ, et al. Perindopril and betablocker for the prevention of cardiac events and mortality in stable coronary artery disease patients: A EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) subanalysis. Am Heart J 2015;170:1092-1098. Go to original source...
    22. Chowdhury R, Khan H, Heydon E. Adherence to cardiovascular therapy: A meta-analysis of prevalence and clinical consequences. Eur Heart J 2013;34:2940-2948. Go to original source...
    23. Castellano JM, Sanz G, Fernandez Ortiz A. A polypill strategy to improve global secondary cardiovascular prevention: from concept to reality. J Am Coll Cardiol 2014;64:613-621. Go to original source...
    24. Mathews R, Peterson ED, Honeycutt E, et al. Early Medication Nonadherence After Acute Myocardial Infarction Insights into Actionable Opportunities From the TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) study. Circ Cardiovasc Qual Outcomes. 2015;8:347-356. Go to original source...
    25. Ho PM, Magid DJ, Shetterly SM, et al, Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J. 2008;155:772-779. Go to original source...
    26. Mancia G, Fagard R, Narkiewicz K, et al. The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) ESH/ESC Guidelines for the management of arterial hypertension. Eur Heart J 2013;34:2159-2221.
    27. Corrao G, Parodi A, Nicotra F, et al. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens 2011;29:610-618. Go to original source...
    28. SPC Prestilol

    Return to the content